What’s New in SILCS v2026
If you missed the live webinar, don’t worry — the full recording is available below. https://www.youtube.com/watch?v=qM9b0n2_L0c&t=1226s In this session, we introduce SILCS v2026, including several new capabilities and workflow enhancements designed to improve interpretability, efficiency, and decision‑making in computational drug discovery. This update may be particularly relevant [...]
SilcsBio Hires Ashlin Poruthoor, Ph.D. as New Applications Scientist
April 21, 2026, Baltimore, MD – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, is excited to announce the hiring of Ashlin Poruthoor, Ph.D. as Applications Scientist. Ashlin has been a post-doctoral fellow with Prof. Alexander MacKerell at the University of Maryland Baltimore [...]
SILCS-Enabled Discovery of Dual HIF Inhibitors Reveals a Powerful New Strategy for Cancer Therapy
Targeting transcription factors that act as master regulators of cancer progression has long been an important goal in oncology drug discovery. Among the most prominent of these are hypoxia-inducible factors 1 and 2 (HIF‑1 and HIF‑2), which orchestrate broad transcriptional programs that drive tumor growth, angiogenesis, metastasis, and immune evasion. [...]
Webinar: SILCS Kinetics
Beyond Binding – Fast, Scalable koff Predictions Powered by SILCS and AI SilcsBio hosted a webinar on January 15th, 2026 showcasing how SILCS‑Kinetics is transforming the study of ligand binding–unbinding kinetics by enabling rapid, scalable predictions of ligand dissociation rates (koff) using a combination of physics‑based modeling and machine learning. [...]
SilcsBio Hires Steven Gossert, Ph.D. as New Applications Scientist
November 20, 2025, Baltimore, MD – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, is excited to announce the hiring of Steven Gossert, Ph.D. as Applications Scientist, Computational Drug Design. Over the last several years, Steven has worked as a postdoctoral modeling scientist [...]
SilcsBio Launches Covalent Suite: Expanding the Power of Computational Drug Design for Covalent Inhibitor Discovery
FOR IMMEDIATE RELEASE Baltimore, MD — October 23, 2025 — SilcsBio, a leader in physics-based computational drug design, is proud to announce the launch of the SilcsBio Software - Covalent Suite, an innovative addition to its expanding portfolio of drug discovery solutions. Designed to accelerate the discovery of targeted covalent inhibitors [...]
